bioceuticals zinc sustain
fit-bioceuticals limited - ascorbic acid,magnesium amino acid chelate,pyridoxine hydrochloride,retinol acetate,zinc amino acid chelate -
xiidra- lifitegrast solution/ drops
takeda pharmaceuticals america, inc. - lifitegrast (unii: 038e5l962w) (lifitegrast - unii:038e5l962w) - lifitegrast 50 mg in 1 ml - xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (ded). xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients in the formulation [see adverse reactions (6.2)] . risk summary there are no available data on xiidra use in pregnant women to inform any drug-associated risks. intravenous (iv) administration of lifitegrast to pregnant rats, from pre-mating through gestation day 17, did not produce teratogenicity at clinically relevant systemic exposures. intravenous administration of lifitegrast to pregnant rabbits during organogenesis produced an increased incidence of omphalocele at the lowest dose tested, 3 mg/kg/day (400-fold the human plasma exposure at the recommended human ophthalmic dose [rhod], based on the area under the curve [auc] level). since human systemic exposure to lifitegrast following ocular administration of xiidra at the rhod is low, the applicability of animal
lifitegrast for solution
aurobindo pharma limited - lifitegrast (unii: 038e5l962w) (lifitegrast - unii:038e5l962w) - lifitegrast ophthalmic solution 5% is indicated for the treatment of the signs and symptoms of dry eye disease (ded). lifitegrast is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients in the formulation [see adverse reactions (6.2)]. risk summary there are no available data on lifitegrast use in pregnant women to inform any drug-associated risks. intravenous (iv) administration of lifitegrast to pregnant rats, from premating through gestation day 17, did not produce teratogenicity at clinically relevant systemic exposures. intravenous administration of lifitegrast to pregnant rabbits during organogenesis produced an increased incidence of omphalocele at the lowest dose tested, 3 mg/kg/day (400-fold the human plasma exposure at the recommended human ophthalmic dose [rhod], based on the area under the curve [auc] level). since human systemic exposure to lifitegrast following ocular administration of lifitegrast at the rhod is low, the applicabili
prostacare
fit-bioceuticals limited - conifer phytosterol complex,crateva magna,cucurbita pepo,lycopene,prunus africana,selenomethionine,secale cereale,zinc amino acid chelate -
ubiquinol bioactive 150mg
fit-bioceuticals limited - ubiquinol-10 -
ultrabiotic 45
fit-bioceuticals limited - bifidobacterium animalis ssp lactis,bifidobacterium bifidum,bifidobacterium breve,lactobacillus acidophilus,lactobacillus casei,lactobacillus fermentum,lactobacillus plantarum,lactobacillus rhamnosus,streptococcus thermophilus -
ultrabiotic 45
fit-bioceuticals limited - bifidobacterium animalis ssp lactis,bifidobacterium bifidum,bifidobacterium breve,lactobacillus acidophilus,lactobacillus casei,lactobacillus fermentum,lactobacillus plantarum,lactobacillus rhamnosus,streptococcus thermophilus -
women's essentials
fit-bioceuticals limited - ascorbic acid,borax,biotin,calcium folinate,calcium pantothenate,calcium phosphate,choline bitartrate,chromium nicotinate,colecalciferol,cyanocobalamin,d-alpha-tocopheryl acid succinate,inositol,levomefolate calcium,magnesium phosphate pentahydrate,manganese amino acid chelate,mecobalamin (co-methylcobalamin),menaquinone 7,molybdenum trioxide,nicotinamide,nicotinic acid,potassium iodide,pyridoxal 5-phosphate monohydrate,pyridoxine hydrochloride,punica granatum,retinol -
theracurmin bioactive 300mg
fit-bioceuticals limited - curcumin -
ultraclean epa/dha plus
fit-bioceuticals limited - concentrated fish omega-3 triglycerides,d-alpha-tocopherol -